So is the new Zhangjiang plant designated to produce surufatinib (when it is approved)? Or is Elunate flying off the shelves in China that they need some expanded capacity to meet the demand? Very positive news indeed. It seems Suru approval is now just a matter of time?
Indeed, this is now the worst performing stock in my portfolio, without news we will miss out the traditional santa rally and we have already missed out on the vaccine rally in the broader market.